Erratum to "Tissue MMP-2 and MMP-9 are better prognostic factors than serum MMP-2/TIMP-2 - complex or TIMP-1 in stage I-III lung carcinoma" [Cancer Letters 236 (2006) 125-132] (DOI:10.1016/j.canlet.2005.05.012);Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in Stage I-III lung carcinoma

Cancer Letters

Volumn 236, Issue 1, 2006, Pages 125-132

  Hoikkala, S ^a   Paakko P ^a   Soini, Y ^a   Makitaro R ^a   Kinnula, V ^b   Turpeenniemi Hujanen, T ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Gelatinase; Immunohistochemistry; Lung cancer; Serum immunoreactive protein; Survival; Tissue inhibitor of metalloproteinase

Indexed keywords

BIOTIN; GELATINASE A; GELATINASE B; MONOCLONAL ANTIBODY; STREPTAVIDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOBECTOMY; LOG RANK TEST; LUNG ADENOCARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STAINING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

EID: 33646082009     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.06.001     Document Type: Erratum

References (30)

1. Brown P.D., Bloxidge R.E., Stuart N.S., Gatter K.C., and Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J. Natl. Cancer Inst. 85 (1993) 574-578
2. Havenith M.G., Dingemans K.P., Cleutjens J.P.M., Wagenaar S.S., and Bosman F.T. Basement membranes in bronchogenic squamous cell carcinoma: an immunohistochemical and ultrastructural study. Ultrastruct. Pathol. 14 (1990) 51-63
3. Polette M., Thiblet J., Ploton D., Buisson A.C., Monboisse J.C., Tournier J.M., and Birembaut P. Distribution of α1(IV) and α3(IV) chains of type IV collagen in lung tumours. J. Pathol. 182 (1997) 185-191
4. Pääkkö P., Risteli J., Risteli L., and Autio-Harmainen H. Immunohistochemical evidence that lung carcinomas grow on alveolar basement membranes. Am. J. Surg. Pathol. 14 (1990) 464-473
5. Soini Y., Pääkkö P., and Autio-Harmainen H. Genes of laminin B1 chain, α1(IV) chain of type IV collagen, and the 72 kD type IV collagenase are mainly expressed by the stromal cells of lung carcinomas. Am. J. Pathol. 142 (1993) 1622-1630
6. Canete-Soler R., Litzky L., Lubensky I., and Muschel R.J. Localization of the 92 kD gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. Am. J. Pathol. 3 (1994) 518-527
7. Gonzalez-Avila G., Iturria C., Vadillo F., Teran L., Selman M., and Perez-Tamayo R. 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells. Pathobiology 66 (1998) 5-16
8. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials an tribulations. Science 29 (2002) 2387-2392
9. Talvensaari-Mattila A., Pääkkö P., Höyhtyä M., Blanco-Sequeiros G., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 6 (1998) 1153-1162
10. Westerlund A., Apaja-Sarkkinen M., Höyhtyä M., Puistola U., and Turpeenniemi-Hujanen T. Gelatinase A-immunoreactive protein in ovarian lesions-prognostic value in epithelial ovarian cancer. Gynecol. Oncol. 75 (1999) 91-98
11. Väisänen A., Kallioinen M., Taskinen P.J., and Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J. Pathol. (1998) 185
12. Liabakk N.B., Talbot I., Smith R.A., Wilkinson K., and Balkwill F. Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 56 (1996) 190-196
13. Gress T.M., Muller-Pillasch F., Lerch M.M., Fries H., Buchler M., and Adler G. Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int. J. Cancer 55 (1993) 10-18
14. Juarez J., Clayman G., Nakajima M., Tanabe K., Hideyuki S., Nicolson G.L., and Boyd D. Role and regulation of expression 92 kDa type IV collagenase (MMP-9) in two invasive squamous cell carcinoma cell lines of the oral cavity. Int. J. Cancer 55 (1993) 10-18
15. Giunciuglio D., Cai T., Filanti C., Manduca P., and Albini A. Effect of osteoblast supernatants on cancer cell migration and invasion. Cancer Lett. 97 (1995) 69-74
16. Kodate M., Kasai T., Hashimoto H., Yasumoto K., Iwata Y., and Manabe H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol. Int. 47 (1997) 461-469
17. Karameris A., Panagou P., Tsilalis T., and Bouros D. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. Am. J. Respir. Crit. Care Med. 156 (1997) 1930-1936
18. Passlick B., Sienel W., Seen-Hibler R., Wöckel W., Thetter O., Mutschler W., and Pantel K. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin. Cancer Res. 6 (2000) 3944-3948
19. Iizasa T., Fujisawa T., Suzuki M., Motohashi S., Yasufuku K., Yasukawa T., et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin. Cancer Res. 5 (1999) 149-153
20. Ylisirniö S., Höyhtyä M., and Turpeenniemi-Hujanen T. Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res. 20 (2000) 1311-1316
21. Laack E., Kohler A., Kugler C., Dierlamm T., Knuffmann C., Vohwinkel G., Niestroy A., et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small cell lung cancer. Ann. Oncol. 13 (2002) 1550-1557
22. Pinto C.A., Carvalho P.E., Antonangelo L., Garippo A., Da Silva A.G., Soares F., et al. Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. Clin. Cancer Res. (2003) 3098-3104
23. Höyhtyä M., Fridman R., Komarek D., Porter-Jordan K., Stetler-Stevenson W.G., Liotta L.A., and Liang C.M. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int. J. Cancer 56 (1994) 500-505
24. Nikkari S.T., Höyhtyä M., Isola J., and Nikkari T. Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am. J. Pathol. 149 (1996) 1427-1433
25. Martinella-Catusse C., Nawrocki B., Gilles C., Birembaut P., and Polette M. Matrix-metalloproteinases in bronchopulmonary carcinomas. Histol. Histopathol. 14 (1999) 839-843
26. Fong K.M., Kida Y., Zimmermann P.V., and Smith P.J. TIMP-1 and adverse prognosis in non-small cell lung cancer. Clin. Cancer Res. 2 (1996) 1369-1372
27. Nawrocki B., Polette M., Marchand V., Monteau M., Gillery P., Tournier J.M., and Birembaut P. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int. J. Cancer 72 (1997) 556-564
28. Junker K. Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer 33 (2001) 17-24
29. Jumper C., Cobos E., and Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir. Med. 98 (2004) 173-177
30. Thorgeirsson U.P., Yoshiji H., Sinha C.C., and Gomez D.E. Breast cancer; tumor neovasculature and the effect of tissue inhibitor of metalloproteinases-1 (TIMP-1) on angiogenesis. In Vivo 10 (1996) 137-144